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ABSTRACT
Introduction: Outpatient parenteral antimicrobial
therapy (OPAT) is used to treat a wide range of
infections, and is common practice in countries such
as the USA and Australia. In the UK, national
guidelines (standards of care) for OPAT services have
been developed to act as a benchmark for clinical
monitoring and quality. However, the availability of
OPAT services in the UK is still patchy and until quite
recently was available only in specialist centres. Over
time, National Health Service (NHS) Trusts have
developed OPAT services in response to local needs,
which has resulted in different service configurations
and models of care. However, there has been no
robust examination comparing the cost-effectiveness of
each service type, or any systematic examination of
patient preferences for services on which to base any
business case decision.
Methods and analysis: The study will use a mixed
methods approach, to evaluate patient preferences for
and the cost-effectiveness of OPAT service models.
The study includes seven NHS Trusts located in four
counties. There are five inter-related work packages:
a systematic review of the published research on the
safety, efficacy and cost-effectiveness of intravenous
antibiotic delivery services; a qualitative study to
explore existing OPAT services and perceived
barriers to future development; an economic model to
estimate the comparative value of four different
community intravenous antibiotic services; a
discrete choice experiment to assess patient
preferences for services, and an expert panel to agree
which service models may constitute the optimal
service model(s) of community intravenous
antibiotics delivery.
Ethics and dissemination: The study has been
approved by the NRES Committee, South West—
Frenchay using the Proportionate Review Service (ref
13/SW/0060). The results of the study will be
disseminated at national and international conferences,
and in international journals.
INTRODUCTION
To meet the challenges of delivering quality
healthcare, health systems must continue to
develop programmes that deliver safe, high-
quality, cost-effective patient care.1 Delivery
of intravenous antibiotics to patients outside
a hospital setting—often termed outpatient
parenteral antimicrobial therapy (OPAT)—
was ﬁrst described on a small scale in the
1970s in North America. By the end of the
1990s, an estimated quarter of a million
patients annually were receiving intravenous
antibiotics on an outpatient basis due to a
range of factors, including cost savings,
patient preference, better intravenous
devices, the introduction of antimicrobial
Strengths and limitations of this study
▪ A key outcome of this study will be an under-
standing of patient preferences for services.
▪ An economic model evaluating the
value-for-money of outpatient parenteral anti-
microbial therapy (OPAT) services.
▪ The potential beneficiaries of the research are
National Health Service (NHS) Trusts and those
responsible for commissioning services as this
will provide a robust evidence base on which to
make service provision decisions.
▪ Policy makers charged with developing national
guidelines for services would benefit from the
knowledge generated and this would be reflected
by well-informed, evidence-based guidance on
the relative value of different service
configurations.
▪ While not a clinical trial, this study offers
insights into the cost-effectiveness of OPAT ser-
vices, and provides evidence on which decisions
relating to the conduct of any future randomised
controlled trial could be based.
Czoski Murray C, et al. BMJ Open 2015;5:e008965. doi:10.1136/bmjopen-2015-008965 1
Open Access Protocol
agents which only needed administration once or twice
a day and the introduction of new OPAT services.2 A
wide variety of infections have been treated through this
system, in particular skin and soft tissue infections,3 but
also infections such as osteomyelitis,4 5 bacteraemia6 and
endocarditis.6 Although widely accepted as the standard
of care in countries such as the USA and Australia, such
services are largely limited to patients with appropriate
health insurance cover.7
OPAT services in the UK started in the 1990s, and were
limited to specialist centres, but services have recently
began to expand, as the beneﬁts to patients and the
healthcare system were recognised.2 Several countries,
including the UK have developed national guidelines
(standards of care) for OPAT services to act as a bench-
mark for clinical monitoring and quality.2 8 9 To support
the development of such services in the UK, the British
Society of Antimicrobial Chemotherapy (BSAC) have
sponsored the development of a toolkit which clinicians
can use to develop a business case for their service. This
toolkit contains SWOT analyses for each service type, but
does not favour any particular model of service design.2
Indeed, there has been no robust examination compar-
ing the cost-effectiveness of each service type, or any sys-
tematic examination of patient preferences for services
on which to base any business case decision. Further bar-
riers to the development of OPAT services are a lack of
any speciﬁc funding system for this in the National
Health Service (NHS), combined with the complexity of
existing charging mechanisms.10
Clinical practice in the UK
Nevertheless, in recent years, OPAT services have devel-
oped in some areas of the UK both in the NHS and
private sectors, largely in response to local pressures in
combination with healthcare staff initiatives.11 This has
led to many service variations using different heathcare
professionals which can be grouped into four main cat-
egories: (1) daily attendance at a hospital outpatient facil-
ity (or community-based clinic); (2) self-administration
or carer administration in the patient’s own home; (3)
provided by community nurses with general skills, for
example, district nurses in the patient’s own home; (4)
provided by specialist nurses, for example, NHS or
private nursing teams, in the patient’s own home.
METHODS AND ANALYSIS
Study objectives
A. Evaluation of the existing evidence of efﬁcacy, safety
and cost-effectiveness of different intravenous anti-
biotic services.
B. Assessment of current OPAT provision by the NHS by
establishing reasons for current service conﬁguration
and identifying barriers to service provision.
C. Economic modelling of the different delivery systems
to evaluate their cost-effectiveness in both short-term
and longer term infection patient groups.
D. Determination of patient preferences for different
community intravenous antibiotic service attributes
through a discrete choice experiment (DCE).
E. Hold an expert panel to agree on what may consti-
tute the optimal service model(s) of community
intravenous antibiotics delivery and how future clin-
ical trials should be designed to test these services.
Design
The study will use a mixed methods approach, combin-
ing qualitative and quantitative methodologies in ﬁve
interconnected work streams. A systematic review of the
published research on the safety, efﬁcacy and cost-
effectiveness of intravenous antibiotic delivery services; a
qualitative study undertaking semistructured telephone
interviews with 25–30 healthcare professionals managing
intravenous antibiotic services in England exploring
models of service offered and any perceived barriers to
future development; an economic model to estimate the
comparative value of four different community intraven-
ous antibiotic services (described above) and allow com-
parisons of the expected costs and beneﬁts of each
service for both short-term and longer term infection
patient groups. We will model the costs and beneﬁts of
running several services concurrently and providing
patients with choices. Determining patient preferences
using a DCE will inform which aspects of treatment are
important to patients and which they would prefer in
the future. Patients will be sampled from those with
short-term infections having less than a week of treat-
ment (eg, cellulitis) and those with deeper infections
requiring longer treatment (eg, bone infections). The
development of the DCE will involve semistructured
interviews with patients and will incorporate any relevant
literature. Lastly, an expert panel with a range of stake-
holders to agree which service models may constitute
the optimal service model(s) of community intravenous
antibiotics delivery, and which are worthy of testing in
clinical trials and to discuss trial design issues.
Setting
The research will be conducted in seven acute trusts;
four in West Yorkshire, one in East Yorkshire, one in
South Yorkshire and one in Oxford.
Systematic review
The aim of the review is to evaluate the existing evi-
dence of efﬁcacy, safety and cost-effectiveness of differ-
ent intravenous antibiotic services.
There are no existing relevant systematic reviews of
this topic, and this work is not an update of an existing
systematic review.
Questions to be considered:
▸ What is the most clinically effective model of deliver-
ing intravenous antibiotics in the community?
▸ What is the most cost-effective model of delivering
intravenous antibiotics in the community?
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▸ What is the most appropriate model for delivering
intravenous antibiotics in the community in terms of
patient safety?
▸ Is community delivery of intravenous antibiotics
acceptable to patients and care providers?
Searches
Two searches will be run to identify (A) studies of intra-
venous antibiotics and known models of care, (B)
reviews of intravenous antibiotics in cellulitis or cystic
ﬁbrosis. The aim of search B is to retrieve papers men-
tioning models of care that we were unaware of when
identifying terms for search A. A range of information
sources will be searched: Bibliographic databases:
MEDLINE, Medline in process, EMBASE, CINAHL,
International Pharmaceutical Abstracts. The Cochrane
Library, Cochrane Library evidence resources: Cochrane
Database of Systematic Reviews, Cochrane Central
Register of Controlled Trials. Economics resources: NHS
Economic Evaluation Database, Research Papers in
Economics (RePEc), Tufts Cost-Effectiveness Analysis
(CEA) Registry, Health Business Elite (HBE).
Supplementary searches of Web of Science
Proceedings, the Health Information Management
Consortium (HMIC), International Pharmaceutical
Abstracts and the website of the British Society for
Antimicrobial Chemotherapy will be conducted to
provide relevant unpublished work. In addition, the ref-
erence lists of included studies will be reviewed for
potentially relevant papers. A sample search strategy is
detailed in appendix A. The period under review is
1993–2013 (with updates planned before the submission
of the ﬁnal report). No language restrictions will be
applied.
Criteria for selection of studies
Studies will be eligible for inclusion if the participants
are individuals or groups of adult patients or care provi-
ders and they evaluate the clinical effectiveness or cost-
effectiveness of an OPAT model, or they describe or
evaluate patient safety issues associated with OPAT, or
they consider the acceptability of OPAT from the per-
spective of the patient receiving treatment or the practi-
tioner delivering care. Any form of intravenous delivery
system will be included (eg, infusion or bolus).
Studies will be excluded if they make reference to clin-
ical effectiveness but do not report on speciﬁc patient
outcomes. Similarly, studies that consider costs related to
a model of delivery without considering patient beneﬁt
alongside these, and studies making reference to costs
and beneﬁts without reporting speciﬁc cost-effectiveness
data (eg, cost per quality-adjusted life year (QALY)) will
also be excluded. Studies that include children will be
reviewed but excluded if they do not report outcomes
for adult patients separately. Studies involving multiple
routes of delivery of antibiotics will be reviewed but will
be excluded if they do not report outcomes for patients
receiving intravenous treatment separately.
The outcomes of interest are clinical effectiveness
(cure or improvement, duration of treatment), cost-
effectiveness (cost, beneﬁt), safety (complications,
adverse events, hospital admission), patient acceptability
and provider acceptability.
Both experimental (randomised controlled trials, con-
trolled clinical trials, controlled before and after studies)
and non-experimental (case–control, cohort, cross-
sectional, other observational) studies will be included.
Quantitative, qualitative and mixed-methodology studies
will be included.
The review and synthesis of data will be undertaken in
accordance with the Centre for Reviews and
Dissemination guidelines for systematic reviews.12 A
protocol of the review was produced and added to the
PROSPERO database (CRD ref: 4201300637 4).
Data extraction
Abstracts of all identiﬁed studies will be screened for
inclusion by one reviewer with a random selection
(20%) independently screened by a second reviewer.
Potentially relevant studies will then be independently
assessed by two reviewers to determine whether they
meet the inclusion criteria. Differences of opinion will
be discussed until a consensus is reached; the opinion of
a third reviewer will be sought where necessary.
Data extraction will be carried out by one reviewer
using a standardised proforma. Extracted data will
include citation details, study purpose, design, location,
setting, duration, population details and clinical
characteristics (reason for antibiotic treatment), models
of care (outpatient, self-administration, general nurse,
specialist nurse or other), topic area (clinical effective-
ness, cost-effectiveness, safety, acceptability), type of anti-
biotic, route of delivery, treatment dose, outcome
measures (if relevant), follow-up and key ﬁndings.
Quality assessment
Quality assessment will be carried out by one reviewer.
The Cochrane Risk of Bias assessment tool will be used
for experimental studies, and the Newcastle-Ottawa
scales for cohort and case–control studies.12 13 We will
use critical interpretive synthesis developed by
Dixon-Woods et al14 to review and analyse any qualitative
literature. The quality of studies reporting economic eva-
luations will be assessed using the Drummond et al15
checklist. Studies will be selected by two researchers
working independently with inconsistencies resolved fol-
lowing discussion.
Studies at risk of bias will not be excluded from the
review, but an appraisal of the strength of existing evi-
dence will be reported, and the review ﬁndings inter-
preted in light of this.
Evidence synthesis
The main characteristics of included studies and ﬁnd-
ings relating to clinical effectiveness, cost-effectiveness,
patient safety and acceptability, and study quality will be
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summarised in narrative and tabular form. We anticipate
that there will be substantial heterogeneity between
included studies, and as such do not plan to pool data
for meta-analysis. The synthesised review data will
provide values for use in the economic model, DCE and
evidence for consideration by the expert panel.
Qualitative study
The aim of this work package is to assess current NHS
OPAT provision by establishing reasons for different
service conﬁgurations and identifying barriers to service
provision.
Design: qualitative telephone interviews
Initially, a brief electronic or telephone survey will be
administered to infection unit managers and/or infec-
tion specialists to establish types of services available in
England. This will be used to identify potential
interviewees.
Sampling
Purposive sampling via a sampling matrix will recruit
participants with different experiences of delivering
OPAT services. A sample of 25–30 infection specialists
and/or unit managers will be recruited. This will ensure
a detailed and comprehensive range of perspectives and
participants.
Data collection
Semistructured, telephone interviews will be conducted
using a topic guide developed from the literature review
and expert opinion (clinician co-applicants/advisors
and Patient and Public Involvement (PPI) members).
The researcher will probe pertinent initial responses
and expand on issues raised. Interviews will be recorded
and transcribed verbatim.
Data analysis
We will use the Framework approach16 to analyse the
data in ﬁve stages: (1) familiarisation with the data, (2)
identifying the thematic framework, (3) indexing, (4)
charting, and (5) mapping and interpreting. This
process enables the researcher to identify emerging
themes or issues in the data. Little is known about why
NHS Trusts choose to deliver speciﬁc OPAT models.
Evidence generated from the literature review and input
from our clinical co-applicants will be used to reﬁne the
thematic framework. The thematic analysis will be modi-
ﬁed in the light of new data, and a process of constant
comparison will be used to examine across themes and
cases. The ﬁndings from the interviews will inform the
modelling and DCE work streams and will be considered
by the expert panel.
Cost-effectiveness
This work package will provide an economic model of
the different delivery systems to evaluate their cost-
effectiveness in both short-term and longer term infec-
tion patients groups.
A decision-analytic model will be developed to esti-
mate the cost-effectiveness of OPAT services. Published
best practice modelling guidelines will be applied.17 The
analysis will conform to the reference case set out by the
National Institute for Health and Care Excellence
(NICE)18 using a cost-utility analysis (CUA) between
service models and effectiveness measured by QALYs. It
is possible that the relative beneﬁts of the service models
may not register in terms of QALY gains (especially for
short-term infections where treatment may last less than
1 week). Therefore, we will also conduct a cost-
effectiveness analysis based on cost per patient success-
fully treated. We will take the perspectives of the health-
care provider and personal social services and of the
patient/carer in separate analyses. Daily hospital treat-
ment service will be considered ‘standard care’ for the
analysis. The model structure will be informed by previ-
ous models in the area and through discussions with
clinicians and patients.
We will adhere to NICE technology appraisal guide-
lines and subsequent Technical Support Documents pro-
duced by the NICE Decision Support Unit in identifying
and selecting parameters.19 Data (eg, NHS resource use
and costs, service model efﬁcacy, event and risk probabil-
ities and utility values) for the economic model will be
derived from the literature review, from the DCE inter-
views, from retrospective retrieval of hospital and
general practitioner records and from clinical experts.
Patients’ use of NHS resources will be captured indir-
ectly from medical records and directly from patient
reports of service use by those participating in the DCE.
Research nurses will extract data (with patient consent)
on treatments received, effectiveness, duration and loca-
tion, treatment delivery systems, additional health ser-
vices used or visits required and adverse events. We aim
to extract a minimum of 400 records across short-term
and long-term infection patients and across services (ie,
n=50 per infection type per service model). All data will
be anonymised. If we have insufﬁcient data on particular
parameters, we may convene a clinical expert and
patient consensus panel to agree on suitable model
values.
Unit costs for treatments, health service staff and
resources will be obtained from the Personal Social
Services Research Unit (PSSRU), the British National
Formulary (BNF) and NHS Reference cost database.
Health state utility values for the CUA will be obtained
from those participating in the DCE completing an
EQ-5D20 questionnaire, which is NICE’s preferred
source of utility values. The EQ-5D is a simple, ﬁve-item
questionnaire which provides utility values based on a
UK general population-derived tariff.
Data analysis
The CUA will compare the three models of community
intravenous antibiotic service delivery to daily hospital
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attendance (considered ‘standard care’). The Markov
decision model will be developed to describe the patient
pathway and potential outcomes and provide estimations
of expected costs and beneﬁts for the service models.
The results will be presented as expected incremental
cost-effectiveness ratio, expected net beneﬁt (assuming λ
is equal to the NICE QALY threshold of £20 000) and a
cost-effectiveness acceptability curve.21 QALYs will be
based on EQ-5D utility values although estimates for
other health states that may be required in the model
(eg, for hospitalisation or hospital-acquired infections)
may come from direct values found in the literature.
Deterministic one-way, multiway and scenario sensitivity
analyses will explore the sensitivity of the results to the
modelling assumptions and parameter values selected.
Probabilistic sensitivity analysis via Monte Carlo simula-
tions will be undertaken to test the robustness of the
results to parameter uncertainty. We will use the value of
information framework to explicitly quantify the implica-
tions of decision uncertainty. We will calculate the
expected value of perfect information22 to help deter-
mine the value of, and priorities for, future research and
the expected value of sample information to design efﬁ-
cient future research. Recently proposed regression
methods for achieving this will be employed.23 This infor-
mation will be used by the team and clinical trial statisti-
cians to plan any future clinical trials.
Discrete choice experiment
This work package will determine patient preferences
for different community intravenous antibiotic service
attributes through the use of a DCE.
The quantitative study of patient preference choices
involves the use of discrete choice models, which are
mathematical structures belonging to the family of
random utility models (for a comprehensive review see
Train24). A substantial number of studies in health eco-
nomics now make use of choice modelling techniques25
and our methodology will follow best practice established
in Lanscar and Louviere.26 Attribute development will be
conducted in two phases using recommendations by
Coast et al27 followed by the development and piloting of
the DCE interview outlined by Willis.28 Information from
the literature review and record retrieval (eg, on treat-
ment effectiveness) will also inform survey content. Our
patient advisory group (PAG) will be closely involved with
this work package, providing input into the development
of study materials (eg, DCE items) and interpretation of
interview data. They will also provide a patient perspec-
tive on the interpretation of the resulting models.
Phase 1 (attribute development)
Design: We will undertake a qualitative exploration of
patient’s experiences of receiving intravenous antibiotic
services and their views on the important aspects of the
service. The use of primary qualitative data to inform
the development of DCEs is relatively recent; therefore,
we will follow guidance developed by Coast et al.27
Sample: Adults (n=30–50) who have experienced com-
munity intravenous antibiotic treatment will be purpos-
ively selected using a sampling matrix ensuring a range
of intravenous antibiotic services, treatment lengths and
diverse backgrounds are represented.
Data collection
Focus groups will be offered to participants to present
their ideas and experiences, and to generate new ideas.
To maximise recruitment, interviews will be offered to
those unable/reluctant to attend a focus group. A topic
guide will be developed from the literature to guide dis-
cussions, and all sessions will be facilitated by experi-
enced researchers. All session will be recorded (with
consent) and transcribed verbatim.
Data analysis
The principle approach will be content analysis, with
data analysed for patterns and themes, to develop cat-
egories and subcategories of attributes to generate a
comprehensive set of attributes. Data will be analysed
iteratively using constant comparative methods29 involv-
ing close reading of the data to identify words that
capture thoughts or concepts. The results of the analysis
will be used to construct the attributes and levels for the
DCE scenarios.
Phase 2 (refinement of terms)
After further reﬁnement, we will pilot the DCE using a
‘think aloud’ cognitive interviewing technique28 with a
‘naive’ sample of participants (n=30) to test understand-
ing and identify problems.
Phase 3 DCE
Sample: Participants will be recruited from the sites pro-
viding each of the services under investigation
(described above). Patients will be eligible if they are
currently receiving intravenous antibiotics in the com-
munity, as an outpatient, or have previously received
such a course of intravenous antibiotics within the past
24 months (identiﬁed retrospectively from records).
Sample size
The sample sizes for DCEs depend on the number of
choice tasks completed by respondents and the number
of attributes and levels presented in each choice. As the
ﬁrst stage of the study is the development of the DCE,
we have used estimates from previous work which would
suggest that 200 participants with short-term and longer
term infections should be sufﬁcient to allow determin-
ation of robust preference data.30 We will use advanced
survey design techniques that maximise the potential for
trading between attributes to enhance the data quality.31
Data collection
The interviews will be carried out by the researcher
using a laptop to present the choices to respondents on
a one-to-one basis.
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DCE questionnaire
We envisage presenting each respondent with 8–10 dif-
ferent choice scenarios. The planned pilot survey will
allow us to determine the most appropriate survey
design.
Data analysis
Data will be analysed using advanced mixture models
allowing us to accommodate the expected high level of
heterogeneity in sensitivities/preferences across individ-
ual patients.32 We will seek to explain this heterogeneity
by linking sensitivities to patient characteristics, and the
use of constructs that allow us to explicitly incorporate
underlying attitudes.33 Any remaining unexplained het-
erogeneity will be accommodated in a random manner.
Hess et al34 35 have shown that an appropriate approach
to the various types of heterogeneity is likely to provide
more robust overall measures of sensitivities. The attitu-
dinal data will also mitigate the effects of any strategic
bias that may arise in the data.
Expert panel
The ﬁnal work package comprises an expert panel to
agree on what may constitute the optimal service model
(s) of community intravenous antibiotics delivery and
how future clinical trials should be designed to test
these services.
The expert panel will consider the evidence generated
from the literature review, economic modelling, DCE
and survey of current service provision. A consensus will
be sought on what is likely to represent optimal commu-
nity intravenous antibiotic therapy for the two patient
groups (long-term and short-term intravenous antibiotic
patients). Membership of the panel will consist of 2–4
service user representatives (including members of our
PAG) together with healthcare staff currently involved in
intravenous antibiotic delivery, pharmacists, GPs, NHS
commissioners, health economists and a clinical trials
statistician.
Data collection and analysis
The expert panel will consider which service delivery
models and which particular conﬁguration of these
models warrant full evaluation in a clinical trial. The
panel will consider the design of future clinical trials,
identifying ways to overcome potential barriers to service
provision and formulate a plan of future research
priorities.
The proposed research will address signiﬁcant gaps in
knowledge about the clinical and cost-effectiveness of
different intravenous antibiotic services; identify which
services patients prefer and which aspects of the services
are most important to them. Since the services available
to patients are likely to have different costs, effects and
risks, it is essential to understand what patients consider
most important in the care they receive and what trade-
offs they are willing to make. The optimal delivery of
OPAT may mean offering patients a choice between
several services concurrently which has consequences
for future planning and resourcing. The panel will be
asked to consider these options.
Consent
Patients with experience of community intravenous anti-
biotic treatment will be approached by the research
nurses either while they are still under the care of the
hospital or retrospectively when then have completed
treatment. All eligible patients will be given a patient
information leaﬂet to consider and if they are willing to
participate they will be consented and registered.
Confidentiality
Monitoring and extraction of data from patient records
will be carried out by the research nurses with the full
consent of the patient and anonymised. Data will be
handled in accordance with the 1998 Data Protection
Act at all times. Patients and staff members who consent
to be interviewed or to participate in focus groups will
be assured of the conﬁdentiality and secure handling of
the recordings and transcripts.
Dissemination policy
An end of project national dissemination meeting is
planned for NHS commissioners and clinicians to
present the ﬁndings of the studies and the recommen-
dations of the expert panel. A lay summary of the
project will be produced for study participants. Findings
will be presented at relevant conferences such as the
National OPAT conference and Federation of Infections
Societies conference. The chief investigator and
co-applicants will be named as authors on main publica-
tions, and an appropriate ﬁrst author agreed through
discussion. Other key individuals will be included as
authors or contributors as appropriate, at the discretion
of the Senior Management Group (SMG). Any disputes
relating to authorship will be resolved by the Steering
Committee.
The Chair and Independent members of the Steering
Committee will be acknowledged, but will not qualify for
full authorship, in order to maintain their independ-
ence. Individual collaborators must not publish data
concerning their participants’ which are directly relevant
to the questions posed in the study until the main
results of the study have been published.
Conclusion
The full potential of OPAT has not yet been realised in
the UK as there is patchy implementation and signiﬁ-
cant variation in services geographically. There is a
paucity of information on which the NHS can base deci-
sions regarding the design, supply and commissioning of
such services and on which national guidance develo-
pers can base recommendations for best practice. OPAT
services have the potential to generate signiﬁcant cost
savings for the NHS and deliver greater patient satisfac-
tion. They may also contribute to the delivery of key
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healthcare strategies and directives such as ‘Equity and
Excellence: Liberating the NHS’ (2010), ‘Creating a
Patient-led NHS’ (2005) and ‘Your Health, Your Care,
Your Say’ (2006).
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